X-Chem debuts OpenDEX software

By The Science Advisory Board staff writers

May 12, 2021 -- X-Chem has announced the launch of its OpenDEX software, which offers access to DNA-encoded libraries and informatics tools offered in the company's drug discovery platform.

Pharmaceutical companies can couple the OpenDEX software with other services such as X-Chem's synthetic chemistry, hit-to-lead, and lead optimization medicinal chemistry services, the company said.

OpenDEX allows researchers to screen billions of small molecules, possibly enhancing their drug discovery programs.

If you like this content, please share it with a colleague!

Related Reading

Orexia to license X-Chem's small molecule program
Orexia announced it will exclusively license the orexin receptor type 2 program from X-Chem for drug discovery.

GHO acquires X-Chem
Global Healthcare Opportunities (GHO) has acquired X-Chem, a biotechnology company that provides drug discovery services via DNA-encoded library technology.

X-Chem, ALK partner on allergy drug discovery
X-Chem announced on February 5 a new drug discovery partnership with ALK-Abelló A/S. The collaboration will focus on the discovery of small-molecule...